{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T11:49:16Z","timestamp":1770983356921,"version":"3.50.1"},"reference-count":45,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,1]]},"abstract":"<jats:sec>\n                    <jats:title>Context.\u2014<\/jats:title>\n                    <jats:p>The International Collaboration on Cancer Reporting (ICCR), supported by major pathology and cancer organizations, aims at the standardization of evidence-based pathology reporting of different types of cancers, with the inclusion of all parameters deemed to be relevant for best patient care and future data collection. Lymph node metastasis is one of the most important prognostic factors in breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective.\u2014<\/jats:title>\n                    <jats:p>To produce a histopathology reporting guide by a panel of recognized experts from the fields of pathology and surgery with elements deemed to be core (required) and noncore (recommended) to report when assessing regional lymph nodes of patients with breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources.\u2014<\/jats:title>\n                    <jats:p>Published literature, previous guidelines\/recommendations, and current cancer staging principles were the basis of the data set drafted by the expert panel. This was discussed in a series of teleconferences and email communications. The draft data set was then made available for public consultation through the ICCR Web site. After this consultation and ICCR ratification, the data set was finalized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.\u2014<\/jats:title>\n                    <jats:p>The ICCR has published a data set for the reporting of surgically removed lymph nodes (including sentinel lymph node biopsy, axillary lymph node dissection, targeted axillary surgery, and lymph node sampling specimens) for breast tumors. This is part of a series of 4 ICCR breast cancer\u2013related data sets. It includes 10 core elements along with 2 noncore elements. This should allow for synoptic reporting, which is more precise, uniform, and complete than nonsynoptic reporting, and leads to improved patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5858\/arpa.2022-0060-ra","type":"journal-article","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T16:41:44Z","timestamp":1666370504000},"page":"1308-1318","source":"Crossref","is-referenced-by-count":5,"title":["Reporting of Surgically Removed Lymph Nodes for Breast Tumors: Recommendations From the International Collaboration on Cancer Reporting"],"prefix":"10.5858","volume":"146","author":[{"given":"G\u00e1bor","family":"Cserni","sequence":"first","affiliation":[{"name":"From the Department of Pathology, Albert Szent-Gy\u00f6rgyi Medical Center, University of Szeged, Szeged, Hungary (Cserni)"},{"name":"The Department of Pathology, B\u00e1cs-Kiskun County Teaching Hospital, Kecskem\u00e9t, Hungary (Cserni)"}]},{"given":"Edi","family":"Brogi","sequence":"additional","affiliation":[{"name":"The Department of Pathology (Brogi), Memorial Sloan Kettering Cancer Center, New York, New York"}]},{"suffix":"III","given":"Hiram S.","family":"Cody","sequence":"additional","affiliation":[{"name":"The Breast Service, Department of Surgery (Cody III), Memorial Sloan Kettering Cancer Center, New York, New York"}]},{"given":"Rahul","family":"Deb","sequence":"additional","affiliation":[{"name":"The Department of Pathology, Royal Derby Hospital, University Hospitals of Derby and Burton, Derby, United Kingdom (Deb)"}]},{"given":"Gelareh","family":"Farshid","sequence":"additional","affiliation":[{"name":"The Department of Anatomical Pathology, SA Pathology, Royal Adelaide Hospital, Adelaide, South Australia, Australia (Farshid)"},{"name":"School of Medicine, Adelaide University, Adelaide, South Australia, Australia (Farshid)"}]},{"given":"Sandra","family":"O'Toole","sequence":"additional","affiliation":[{"name":"The Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia (O'Toole)"},{"name":"Sydney Medical School, University New South Wales, Sydney, New South Wales, Australia (O'Toole)"}]},{"given":"Elena","family":"Provenzano","sequence":"additional","affiliation":[{"name":"NIHR Cambridge Biomedical Research Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom (Provenzano)"},{"name":"The Department of Histopathology, Addenbrookes Hospital, Cambridge, United Kingdom (Provenzano)"}]},{"given":"Cecily M.","family":"Quinn","sequence":"additional","affiliation":[{"name":"The Department of Histopathology, BreastCheck, Irish National Breast Screening Programme & St. Vincent's University Hospital, Dublin, Ireland (Quinn)"},{"name":"University College Dublin, School of Medicine, Dublin, Ireland (Quinn)"}]},{"given":"Aysegul A.","family":"Sahin","sequence":"additional","affiliation":[{"name":"Division of Pathology and Laboratory Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas (Sahin)"}]},{"given":"Fernando","family":"Schmitt","sequence":"additional","affiliation":[{"name":"The Department of Pathology, Medical Faculty of Porto University, and Molecular Unit, Institute of Pathology and Immunology of Porto University, Porto, Portugal (Schmitt)"},{"name":"RISE (Health Research Network) @ CINTESIS (Center for Health Technology and Services Research), Porto, Portugal (Schmitt)"}]},{"given":"Donald L.","family":"Weaver","sequence":"additional","affiliation":[{"name":"The Department of Pathology, University of Vermont Larner College of Medicine, Burlington (Weaver)"}]},{"given":"Rin","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"The Department of Pathology and Laboratory Medicine, Kurume University Medical Center, Fukuoka, Japan (Yamaguchi)"}]},{"given":"Fleur","family":"Webster","sequence":"additional","affiliation":[{"name":"International Collaboration on Cancer Reporting, Sydney, NSW, Australia, and ICCR Project Manager, Surry Hills, Australia (Webster)"}]},{"given":"Puay Hoon","family":"Tan","sequence":"additional","affiliation":[{"name":"The Division of Pathology, Singapore General Hospital, Academia, Singapore (Tan)"},{"name":"Cambridge Experimental Cancer Medicine Centre (ECMR), Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom"}]}],"member":"3906","published-online":{"date-parts":[[2022,10,20]]},"reference":[{"key":"2022102120411298900_i1543-2165-146-11-1308-b01","unstructured":"International Collaboration on Cancer Reporting.\n          www.iccr-cancer.org. Accessed\n\t\t\t\t\tMarch12,2022."},{"key":"2022102120411298900_i1543-2165-146-11-1308-b02","doi-asserted-by":"crossref","unstructured":"Srigley\n              JR,\n            \n            \n              Judge\n              M,\n            \n            \n              Helliwell\n              T,\n            \n            \n              Birdsong\n              GG,\n            \n            \n              Ellis\n              DW.\n            \n          \n          The International Collaboration on Cancer Reporting (ICCR): a decade of progress towards global pathology standardisation and data interoperability.\n\t\t\t\t\tHistopathology.\n\t\t\t\t\t2021;\n\t\t\t\t\t79:\n\t\t\t\t\t897\u2013\n\t\t\t\t\t901.","DOI":"10.1111\/his.14431"},{"key":"2022102120411298900_i1543-2165-146-11-1308-b03","doi-asserted-by":"crossref","unstructured":"Merlin\n              T,\n            \n            \n              Weston\n              A,\n            \n            \n              Tooher\n              R.\n            \n          \n          Extending an evidence hierarchy to include topics other than treatment: revising the Australian \u2018levels of evidence'.\n\t\t\t\t\tBMC Med Res Methodol.\n\t\t\t\t\t2009;\n\t\t\t\t\t9:\n\t\t\t\t\t34.\n\t\t\t\t\tdoi:10.1186\/1471-2288-9-34","DOI":"10.1186\/1471-2288-9-34"},{"key":"2022102120411298900_i1543-2165-146-11-1308-b04","unstructured":"Cserni\n              G,\n            \n            \n              Brogi\n              E,\n            \n            \n              Cody\n              HS\n              III,\n            \n            et al.\n          \n          \n            Surgically Removed Lymph Nodes for Breast Tumours Histopathology Reporting Guide. Sydney, Australia: International Collaboration on Cancer Reporting;\n          2021."},{"key":"2022102120411298900_i1543-2165-146-11-1308-b05","doi-asserted-by":"crossref","unstructured":"Cserni\n              G,\n            \n            \n              Maguire\n              A,\n            \n            \n              Bianchi\n              S,\n            \n            \n              Ryska\n              A,\n            \n            \n              Kov\u00e1cs\n              A.\n            \n          \n          Sentinel lymph node assessment in breast cancer-an update on current recommendations.\n\t\t\t\t\tVirchows Arch.\n\t\t\t\t\t2022;\n\t\t\t\t\t480(1):\n\t\t\t\t\t95\u2013\n\t\t\t\t\t107.","DOI":"10.1007\/s00428-021-03128-z"},{"key":"2022102120411298900_i1543-2165-146-11-1308-b06","doi-asserted-by":"crossref","unstructured":"Krag\n              DN,\n            \n            \n              Anderson\n              SJ,\n            \n            \n              Julian\n              TB,\n            \n            et al.\n          \n          Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial.\n\t\t\t\t\tLancet Oncol.\n\t\t\t\t\t2010;\n\t\t\t\t\t11(10):\n\t\t\t\t\t927\u2013\n\t\t\t\t\t933.","DOI":"10.1016\/S1470-2045(10)70207-2"},{"key":"2022102120411298900_i1543-2165-146-11-1308-b07","doi-asserted-by":"crossref","unstructured":"Galimberti\n              V,\n            \n            \n              Cole\n              BF,\n            \n            \n              Zurrida\n              S,\n            \n            et al.\n          \n          Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial.\n\t\t\t\t\tLancet Oncol.\n\t\t\t\t\t2013;\n\t\t\t\t\t14(4):\n\t\t\t\t\t297\u2013\n\t\t\t\t\t305.","DOI":"10.1016\/S1470-2045(13)70035-4"},{"key":"2022102120411298900_i1543-2165-146-11-1308-b08","doi-asserted-by":"crossref","unstructured":"Galimberti\n              V,\n            \n            \n              Cole\n              BF,\n            \n            \n              Viale\n              G,\n            \n            et al.\n          \n          Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial.\n\t\t\t\t\tLancet Oncol.\n\t\t\t\t\t2018;\n\t\t\t\t\t19(10):\n\t\t\t\t\t1385\u2013\n\t\t\t\t\t1393.","DOI":"10.1016\/S1470-2045(18)30380-2"},{"key":"2022102120411298900_i1543-2165-146-11-1308-b09","doi-asserted-by":"crossref","unstructured":"Giuliano\n              AE,\n            \n            \n              Hunt\n              KK,\n            \n            \n              Ballman\n              KV,\n            \n            et al.\n          \n          Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial.\n\t\t\t\t\tJAMA.\n\t\t\t\t\t2011;\n\t\t\t\t\t305(6):\n\t\t\t\t\t569\u2013\n\t\t\t\t\t575.","DOI":"10.1001\/jama.2011.90"},{"key":"2022102120411298900_i1543-2165-146-11-1308-b10","doi-asserted-by":"crossref","unstructured":"Giuliano\n              AE,\n            \n            \n              Ballman\n              KV,\n            \n            \n              McCall\n              L,\n            \n            et al.\n          \n          Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) Randomized Clinical Trial.\n\t\t\t\t\tJAMA.\n\t\t\t\t\t2017;\n\t\t\t\t\t318(10):\n\t\t\t\t\t918\u2013\n\t\t\t\t\t926.","DOI":"10.1001\/jama.2017.11470"},{"key":"2022102120411298900_i1543-2165-146-11-1308-b11","doi-asserted-by":"crossref","unstructured":"Donker\n              M,\n            \n            \n              van Tienhoven\n              G,\n            \n            \n              Straver\n              ME,\n            \n            et al.\n          \n          Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial.\n\t\t\t\t\tLancet Oncol.\n\t\t\t\t\t2014;\n\t\t\t\t\t15(12):\n\t\t\t\t\t1303\u2013\n\t\t\t\t\t1310.","DOI":"10.1016\/S1470-2045(14)70460-7"},{"key":"2022102120411298900_i1543-2165-146-11-1308-b12","doi-asserted-by":"crossref","unstructured":"S\u00e1volt\n              \u00c1,\n            \n            \n              P\u00e9ley\n              G,\n            \n            \n              Polg\u00e1r\n              C,\n            \n            et al.\n          \n          Eight-year follow up result of the OTOASOR trial: the Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: a randomized, single centre, phase III, non-inferiority trial.\n\t\t\t\t\tEur J Surg Oncol.\n\t\t\t\t\t2017;\n\t\t\t\t\t43(4):\n\t\t\t\t\t672\u2013\n\t\t\t\t\t679.","DOI":"10.1016\/j.ejso.2016.12.011"},{"key":"2022102120411298900_i1543-2165-146-11-1308-b13","doi-asserted-by":"crossref","unstructured":"Lyman\n              GH,\n            \n            \n              Temin\n              S,\n            \n            \n              Edge\n              SB,\n            \n            et al.\n          \n          Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update.\n\t\t\t\t\tJ Clin Oncol.\n\t\t\t\t\t2014;\n\t\t\t\t\t32(13):\n\t\t\t\t\t1365\u2013\n\t\t\t\t\t1383.","DOI":"10.1200\/JCO.2013.54.1177"},{"key":"2022102120411298900_i1543-2165-146-11-1308-b14","unstructured":"Amin\n              MB,\n            \n            \n              Edge\n              S,\n            \n            \n              Greene\n              FL,\n            \n          \n          et al, eds. AJCC Cancer Staging Manual. 8th ed.\n\t\t\t\t\tNew York:\n\t\t\t\t\tSpringer;2017."},{"key":"2022102120411298900_i1543-2165-146-11-1308-b15","unstructured":"American Joint Committee on Cancer.\n          Updated breast chapter for 8th edition of AJCC Cancer Staging Manual.\n\t\t\t\t\thttps:\/\/cancerstaging.org\/references-tools\/deskreferences\/Documents\/AJCC%20Breast%20Cancer%20Staging%20System.pdf. Accessed March 31,2021."},{"key":"2022102120411298900_i1543-2165-146-11-1308-b16","doi-asserted-by":"crossref","unstructured":"Wittekind\n              C,\n            \n            \n              Brierley\n              JD,\n            \n            \n              Lee\n              A,\n            \n            \n              van Eycken\n              E,\n            \n          \n          eds.\n          \n            TNM Supplement: A Commentary on Uniform Use. 5th ed.\n\t\t\t\t\tHoboken, NJ:\n\t\t\t\t\tWiley;2019.","DOI":"10.1002\/9781119263975"},{"key":"2022102120411298900_i1543-2165-146-11-1308-b17","unstructured":"Brierley\n              JD,\n            \n            \n              Gospodarowicz\n              MK,\n            \n            \n              Wittekind\n              C,\n            \n          \n          eds.\n          \n            Union for International Cancer Control. TNM Classification of Malignant Tumours. 8th ed.\n\t\t\t\t\tHoboken, NJ:\n\t\t\t\t\tWiley;2016."},{"key":"2022102120411298900_i1543-2165-146-11-1308-b18","doi-asserted-by":"crossref","unstructured":"Cserni\n              G,\n            \n            \n              Amendoeira\n              I,\n            \n            \n              Bianchi\n              S,\n            \n            et al.\n          \n          Distinction of isolated tumour cells and micrometastasis in lymph nodes of breast cancer patients according to the new Tumour Node Metastasis (TNM) definitions.\n\t\t\t\t\tEur J Cancer.\n\t\t\t\t\t2011;\n\t\t\t\t\t47(6):\n\t\t\t\t\t887\u2013\n\t\t\t\t\t894.","DOI":"10.1016\/j.ejca.2010.11.011"},{"key":"2022102120411298900_i1543-2165-146-11-1308-b19","doi-asserted-by":"crossref","unstructured":"Weaver\n              DL,\n            \n            \n              Ashikaga\n              T,\n            \n            \n              Krag\n              DN,\n            \n            et al.\n          \n          Effect of occult metastases on survival in node-negative breast cancer.\n\t\t\t\t\tN Engl J Med.\n\t\t\t\t\t2011;\n\t\t\t\t\t364(5):\n\t\t\t\t\t412\u2013\n\t\t\t\t\t421.","DOI":"10.1056\/NEJMoa1008108"},{"key":"2022102120411298900_i1543-2165-146-11-1308-b20","doi-asserted-by":"crossref","unstructured":"Giuliano\n              AE,\n            \n            \n              Hawes\n              D,\n            \n            \n              Ballman\n              KV,\n            \n            et al.\n          \n          Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer.\n\t\t\t\t\tJAMA.\n\t\t\t\t\t2011;\n\t\t\t\t\t306(4):\n\t\t\t\t\t385\u2013\n\t\t\t\t\t393.","DOI":"10.1001\/jama.2011.1034"},{"key":"2022102120411298900_i1543-2165-146-11-1308-b21","doi-asserted-by":"crossref","unstructured":"Provenzano\n              E,\n            \n            \n              Bossuyt\n              V,\n            \n            \n              Viale\n              G,\n            \n            et al.\n          \n          Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group.\n\t\t\t\t\tMod Pathol.\n\t\t\t\t\t2015;\n\t\t\t\t\t28(9):\n\t\t\t\t\t1185\u2013\n\t\t\t\t\t1201.","DOI":"10.1038\/modpathol.2015.74"},{"key":"2022102120411298900_i1543-2165-146-11-1308-b22","unstructured":"College of American Pathologists.\n          \n            Protocol for the Examination of Resection Specimens From Patients With Invasive Carcinoma of the Breast, Version 4.4.0.0. February 2020.\n\t\t\t\t\thttps:\/\/documents.cap.org\/protocols\/cp-breast-invasive-resection-20-4400.pdf. Accessed September 22,2020."},{"key":"2022102120411298900_i1543-2165-146-11-1308-b23","doi-asserted-by":"crossref","unstructured":"Symmans\n              WF,\n            \n            \n              Peintinger\n              F,\n            \n            \n              Hatzis\n              C,\n            \n            et al.\n          \n          Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.\n\t\t\t\t\tJ Clin Oncol.\n\t\t\t\t\t2007;\n\t\t\t\t\t25(28):\n\t\t\t\t\t4414\u2013\n\t\t\t\t\t4422.","DOI":"10.1200\/JCO.2007.10.6823"},{"key":"2022102120411298900_i1543-2165-146-11-1308-b24","doi-asserted-by":"crossref","unstructured":"Kuehn\n              T,\n            \n            \n              Bauerfeind\n              I,\n            \n            \n              Fehm\n              T,\n            \n            et al.\n          \n          Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study.\n\t\t\t\t\tLancet Oncol.\n\t\t\t\t\t2013;\n\t\t\t\t\t14(7):\n\t\t\t\t\t609\u2013\n\t\t\t\t\t618.","DOI":"10.1016\/S1470-2045(13)70166-9"},{"key":"2022102120411298900_i1543-2165-146-11-1308-b25","doi-asserted-by":"crossref","unstructured":"Boileau\n              JF,\n            \n            \n              Poirier\n              B,\n            \n            \n              Basik\n              M,\n            \n            et al.\n          \n          Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study.\n\t\t\t\t\tJ Clin Oncol.\n\t\t\t\t\t2015;\n\t\t\t\t\t33(3):\n\t\t\t\t\t258\u2013\n\t\t\t\t\t264.","DOI":"10.1200\/JCO.2014.55.7827"},{"key":"2022102120411298900_i1543-2165-146-11-1308-b26","doi-asserted-by":"crossref","unstructured":"Boughey\n              JC,\n            \n            \n              Suman\n              VJ,\n            \n            \n              Mittendorf\n              EA,\n            \n            et al.\n          \n          Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.\n\t\t\t\t\tJAMA.\n\t\t\t\t\t2013;\n\t\t\t\t\t310(14):\n\t\t\t\t\t1455\u2013\n\t\t\t\t\t1461.","DOI":"10.1001\/jama.2013.278932"},{"key":"2022102120411298900_i1543-2165-146-11-1308-b27","doi-asserted-by":"crossref","unstructured":"Boughey\n              JC,\n            \n            \n              Ballman\n              KV,\n            \n            \n              Le-Petross\n              HT,\n            \n            et al.\n          \n          Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0-T4, N1-N2) who receive neoadjuvant chemotherapy: results from ACOSOG Z1071 (Alliance).\n\t\t\t\t\tAnn Surg.\n\t\t\t\t\t2016;\n\t\t\t\t\t263(4):\n\t\t\t\t\t802\u2013\n\t\t\t\t\t807.","DOI":"10.1097\/SLA.0000000000001375"},{"key":"2022102120411298900_i1543-2165-146-11-1308-b28","doi-asserted-by":"crossref","unstructured":"Van Zee\n              KJ,\n            \n            \n              Manasseh\n              DM,\n            \n            \n              Bevilacqua\n              JL,\n            \n            et al.\n          \n          A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy.\n\t\t\t\t\tAnn Surg Oncol.\n\t\t\t\t\t2003;\n\t\t\t\t\t10(10):\n\t\t\t\t\t1140\u2013\n\t\t\t\t\t1151.","DOI":"10.1245\/ASO.2003.03.015"},{"key":"2022102120411298900_i1543-2165-146-11-1308-b29","doi-asserted-by":"crossref","unstructured":"van la Parra\n              RF,\n            \n            \n              MF\n              Ernst,\n            \n            \n              Bevilacqua\n              JL,\n            \n            et al.\n          \n          Validation of a nomogram to predict the risk of nonsentinel lymph node metastases in breast cancer patients with a positive sentinel node biopsy: validation of the MSKCC breast nomogram.\n\t\t\t\t\tAnn Surg Oncol.\n\t\t\t\t\t2009;\n\t\t\t\t\t16(5):\n\t\t\t\t\t1128\u2013\n\t\t\t\t\t1135.","DOI":"10.1245\/s10434-009-0359-y"},{"key":"2022102120411298900_i1543-2165-146-11-1308-b30","doi-asserted-by":"crossref","unstructured":"van la Parra\n              RF,\n            \n            \n              Peer\n              PG,\n            \n            \n              MF\n              Ernst,\n            \n            \n              Bosscha\n              K.\n            \n          \n          Meta-analysis of predictive factors for non-sentinel lymph node metastases in breast cancer patients with a positive SLN.\n\t\t\t\t\tEur J Surg Oncol.\n\t\t\t\t\t2011;\n\t\t\t\t\t37(4):\n\t\t\t\t\t290\u2013\n\t\t\t\t\t299.","DOI":"10.1016\/j.ejso.2011.01.006"},{"key":"2022102120411298900_i1543-2165-146-11-1308-b31","doi-asserted-by":"crossref","unstructured":"Cserni\n              G.\n            \n          \n          Meta-analysis of predictive factors for non-sentinel lymph node metastases in breast cancer patients with a positive SLN.\n\t\t\t\t\tBreast Diseases: A Year Book Quarterly.\n\t\t\t\t\t2011;\n\t\t\t\t\t22(4):\n\t\t\t\t\t390\u2013\n\t\t\t\t\t391.","DOI":"10.1016\/j.breastdis.2011.10.048"},{"key":"2022102120411298900_i1543-2165-146-11-1308-b32","doi-asserted-by":"crossref","unstructured":"Cserni\n              G.\n            \n          \n          Sentinel node biopsy and nodal staging.\n\t\t\t\t\tIn:KahanZ,TotT,eds.Breast Cancer, A Heterogeneous Disease Entity: The Very Early Stages.\n\t\t\t\t\tDordrecht-Heidelberg-London-New York:\n\t\t\t\t\tSpringer Science+Business Media;2011:\n\t\t\t\t\t149\u2013\n\t\t\t\t\t184.","DOI":"10.1007\/978-94-007-0489-3_7"},{"key":"2022102120411298900_i1543-2165-146-11-1308-b33","doi-asserted-by":"crossref","unstructured":"Nottegar\n              A,\n            \n            \n              Veronese\n              N,\n            \n            \n              Senthil\n              M,\n            \n            et al.\n          \n          Extra-nodal extension of sentinel lymph node metastasis is a marker of poor prognosis in breast cancer patients: a systematic review and an exploratory meta-analysis.\n\t\t\t\t\tEur J Surg Oncol.\n\t\t\t\t\t2016;\n\t\t\t\t\t42(7):\n\t\t\t\t\t919\u2013\n\t\t\t\t\t925.","DOI":"10.1016\/j.ejso.2016.02.259"},{"key":"2022102120411298900_i1543-2165-146-11-1308-b34","unstructured":"Wells\n              CA,\n            \n            \n              Amendoeira\n              I,\n            \n            \n              Bellocq\n              JP,\n            \n            et al.\n          \n          S2: pathology update\u2014quality assurance guidelines for pathology.\n\t\t\t\t\tIn:PerryN,BroedersM,de WolfC,T\u00f6rnbergS,HollandR,von KarsaL,eds.European Guidelines for Quality Assurance in Breast Cancer Screening and Diagnosis. 4th ed (supplements).\n\t\t\t\t\tLuxembourg:\n\t\t\t\t\tEuropean Commission, Office for Official Publications of the European Union;2013."},{"key":"2022102120411298900_i1543-2165-146-11-1308-b35","doi-asserted-by":"crossref","unstructured":"Cserni\n              G.\n            \n          \n          Intraoperative analysis of sentinel lymph nodes in breast cancer by one-step nucleic acid amplification.\n\t\t\t\t\tJ Clin Pathol.\n\t\t\t\t\t2012;\n\t\t\t\t\t65(3):\n\t\t\t\t\t193\u2013\n\t\t\t\t\t199.","DOI":"10.1136\/jclinpath-2011-200301"},{"key":"2022102120411298900_i1543-2165-146-11-1308-b36","unstructured":"National Institute for Health and Care Excellence.\n          Intraoperative tests (RD-100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer. 2013.\n\t\t\t\t\thttps:\/\/www.nice.org.uk\/guidance\/dg8\/chapter\/1-Recommendations. Accessed June 1,2020."},{"key":"2022102120411298900_i1543-2165-146-11-1308-b37","doi-asserted-by":"crossref","unstructured":"Halsted\n              CP,\n            \n            \n              Benson\n              JR,\n            \n            \n              Jatoi\n              I.\n            \n          \n          A historical account of breast cancer surgery: beware of local recurrence but be not radical.\n\t\t\t\t\tFuture Oncol.\n\t\t\t\t\t2014;\n\t\t\t\t\t10(9):\n\t\t\t\t\t1649\u2013\n\t\t\t\t\t1657.","DOI":"10.2217\/fon.14.98"},{"key":"2022102120411298900_i1543-2165-146-11-1308-b38","doi-asserted-by":"crossref","unstructured":"Giuliano\n              AE,\n            \n            \n              Dale\n              PS,\n            \n            \n              Turner\n              RR,\n            \n            \n              Morton\n              DL,\n            \n            \n              Evans\n              SW,\n            \n            \n              Krasne\n              DL.\n            \n          \n          Improved axillary staging of breast cancer with sentinel lymphadenectomy.\n\t\t\t\t\tAnn Surg.\n\t\t\t\t\t1995;\n\t\t\t\t\t222(3):\n\t\t\t\t\t394\u2013\n\t\t\t\t\t401.","DOI":"10.1097\/00000658-199509000-00016"},{"key":"2022102120411298900_i1543-2165-146-11-1308-b39","doi-asserted-by":"crossref","unstructured":"Cserni\n              G,\n            \n            \n              Amendoeira\n              I,\n            \n            \n              Apostolikas\n              N,\n            \n            et al.\n          \n          Pathological work-up of sentinel lymph nodes in breast cancer: review of current data to be considered for the formulation of guidelines.\n\t\t\t\t\tEur J Cancer.\n\t\t\t\t\t2003;\n\t\t\t\t\t39(12):\n\t\t\t\t\t1654\u2013\n\t\t\t\t\t1667.","DOI":"10.1016\/S0959-8049(03)00203-X"},{"key":"2022102120411298900_i1543-2165-146-11-1308-b40","doi-asserted-by":"crossref","unstructured":"Cserni\n              G,\n            \n            \n              Amendoeira\n              I,\n            \n            \n              Apostolikas\n              N,\n            \n            et al.\n          \n          Discrepancies in current practice of pathological evaluation of sentinel lymph nodes in breast cancer: results of a questionnaire based survey by the European Working Group for Breast Screening Pathology.\n\t\t\t\t\tJ Clin Pathol.\n\t\t\t\t\t2004;\n\t\t\t\t\t57(7):\n\t\t\t\t\t695\u2013\n\t\t\t\t\t701.","DOI":"10.1136\/jcp.2003.013599"},{"key":"2022102120411298900_i1543-2165-146-11-1308-b41","doi-asserted-by":"crossref","unstructured":"Asirvatham\n              JR,\n            \n            \n              Jorns\n              JM.\n            \n          \n          How do pathologists in academic institutions across the United States and Canada evaluate sentinel lymph nodes in breast cancer: a practice survey.\n\t\t\t\t\tAm J Clin Pathol.\n\t\t\t\t\t2021;\n\t\t\t\t\t156(6):\n\t\t\t\t\t980\u2013\n\t\t\t\t\t988.","DOI":"10.1093\/ajcp\/aqab055"},{"key":"2022102120411298900_i1543-2165-146-11-1308-b42","doi-asserted-by":"crossref","unstructured":"Weaver\n              DL.\n            \n          \n          Pathology evaluation of sentinel lymph nodes in breast cancer: protocol recommendations and rationale.\n\t\t\t\t\tMod Pathol.\n\t\t\t\t\t2010;\n\t\t\t\t\t23(suppl 2):\n\t\t\t\t\tS26\u2013\n\t\t\t\t\tS32.","DOI":"10.1038\/modpathol.2010.36"},{"key":"2022102120411298900_i1543-2165-146-11-1308-b43","unstructured":"Fox\n              S,\n            \n            \n              Chen\n              CJ,\n            \n            \n              Chua\n              B,\n            \n            et al.\n          \n          (2021).\n\t\t\t\t\tDuctal Carcinoma In Situ, Variants of Lobular Carcinoma In Situ and Low Grade Lesions Histopathology Reporting Guide. Sydney, Australia: International Collaboration on Cancer Reporting; 2021.http:\/\/www.iccr-cancer.org\/datasets\/published-datasets\/breast\/dcis-variants-of-lcis-and-low-grade-lesions. Accessed January 18,2022."},{"key":"2022102120411298900_i1543-2165-146-11-1308-b44","unstructured":"Ellis\n              I,\n            \n            \n              Allison\n              KH,\n            \n            \n              Dang\n              C,\n            \n            et al.\n          \n          \n            Invasive Carcinoma of the Breast Histopathology Reporting Guide. Sydney, Australia: International Collaboration on Cancer Reporting; 2021.\n\t\t\t\t\thttp:\/\/www.iccr-cancer.org\/datasets\/published-datasets\/breast\/invasive-carcinoma-of-the-breast. Accessed January 18,2022."},{"key":"2022102120411298900_i1543-2165-146-11-1308-b45","unstructured":"Bossuyt\n              V,\n            \n            \n              Provenzano\n              E,\n            \n            \n              Symmans\n              WF,\n            \n            et al.\n          \n          \n            Invasive Carcinoma of the Breast in the Setting of Neoadjuvant Therapy Histopathology Reporting Guide. Sydney, Australia: International Collaboration on Cancer Reporting; 2022.\n          \n            http:\/\/www.iccr-cancer.org\/datasets\/published-datasets\/breast. Forthcoming June\/July 2022."}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/aplm\/article-pdf\/146\/11\/1308\/3134594\/i1543-2165-146-11-1308.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/aplm\/article-pdf\/146\/11\/1308\/3134594\/i1543-2165-146-11-1308.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:38:59Z","timestamp":1764790739000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/146\/11\/article-p1308.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,20]]},"references-count":45,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,10,20]]},"published-print":{"date-parts":[[2022,11,1]]}},"URL":"https:\/\/doi.org\/10.5858\/arpa.2022-0060-ra","relation":{},"ISSN":["1543-2165","0003-9985"],"issn-type":[{"value":"1543-2165","type":"electronic"},{"value":"0003-9985","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,20]]}}}